Impact of Clinician Virtual Human Interaction Training in Emotional Self-Awareness on Patients Suicidal Ideation and Suicide Crisis Syndrome

November 20, 2022 updated by: Igor Galynker, Icahn School of Medicine at Mount Sinai

Impact of Clinician Virtual Human Interaction Training in Emotional Self-Awareness on Patients Suicidal Ideation and Suicide Crisis Syndrome: a Randomized Controlled Trial

Working with patients at risk for suicide is highly stressful for clinicians and often elicits powerful negative emotional responses that may adversely affect suicidal outcomes. A proposed explanation has been that negative emotional responses may result in less empathic communication and unwitting rejection of the patient, which is liable to damage therapeutic alliance. Thus, there is a need for clinician training in effective management of negative emotions towards suicidal patients, which can result in tangible improvement in suicidal outcomes. The training must be web-based, scalable and easy to disseminate, making it available to clinicians everywhere.

In this project, the study team will address this critical need by using Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA), which includes both recognition of one's own negative emotional responses, and ability to engage in verbal empathic communication with acutely suicidal patients. The study team will conduct a prospective multisite, blinded, randomized trial comparing VHI ESA training with a Control condition, which will assess both clinician-level and patient-level outcomes in 80 outpatient clinician participants (CPs) and 400 of their participating patients (PPs). Using the same VHI scenarios, the ESA group will receive clinician-focused, comprehensive feedback in ESA, while the Control group will assess the VH's suicide risk without receiving the ESA feedback. The study team will measure efficacy of the VHI ESA training on clinicians by comparing ESA feedback and Control CPs' post-training (T2) ESA towards virtual humans, adjusting for pre-training (T1) ESA. The study team will measure the impact of the VHI ESA training on patients' suicidal outcomes by assessing the primary and secondary outcome variables in both CPs and PPs three times: at baseline (T0), after the first post-training treatment session (T3) and one-month post-training (T4). The study team will examine the role of therapeutic alliance as a possible mediator of the relationship between clinicians' ESA and their patients' Suicidal Ideation (SI) and Suicide Crisis Syndrome (SCS).

To accomplish this goal, the study team will use the novel validated suicide risk assessment instruments developed in preliminary studies: the Therapist Response Questionnaire - Suicide Form (TRQ-SF), which assesses negative emotional responses to suicidal patients, and the Suicide Crisis inventory (SCI), which assesses the SCS severity and predicts near-term suicidal behavior. For web-based VHI training the study team will use the already tested and disseminated web-based empathy-teaching platform, coupled with an assessment of verbal empathy measured by the Empathic Communication Coding System (ECCS).

Study Overview

Status

Completed

Conditions

Detailed Description

The study has three interconnected Specific Aims.

In Aim 1 the study team will determine if, VHI ESA clinician training improves ESA when interacting with virtual humans. The study team hypothesizes that clinicians in the ESA group will report less negative emotional responses and greater empathic communication at the post-training (T2) assessment than clinicians in the Control group, adjusting for pre-treatment (T1) scores.

In Aim 2 the study team will establish if, VHI ESA clinician training results in sustained improvement in patients' suicidal ideation and SCS. The study team's primary patient level outcomes will be SI as measured by the Beck Suicide Scale, and SCS severity as measured by the SCI. The study team's secondary outcomes will be treatment retention, patients' perception of the therapeutic alliance as measured by the Working Alliance Inventory, patients' perception of clinician empathy as measured by the Consultational and Relational Empathy scale, treatment adherence as measured by the Morisky Medication Adherence Scale, and suicidal behaviors as measured by the Columbia Suicide Severity Rating Scale. The study team hypothesizes that patient participants in the ESA group will report less severe SI and SCS at the first post-training clinical encounter with their clinician (T3) than the Control group, adjusting for baseline (T0) levels of SI and SCS, and that these differences will extend to the final post-training follow-up (T4).

In Aim 3 the study team will assess the role of therapeutic alliance in improving SI and SCS. The study team hypothesizes that patients' therapeutic alliance at post-training assessments T3 and T4 will mediate the relationship between post-training ESA indices and post-training patient suicidal outcomes, adjusting for baseline (T0) levels of the outcome.

If successful, the proposed work may have a broad impact on clinician training and practice by adding an ESA dimension to evidence-based suicide risk assessment. Suicide is preventable and the ultimate goal is to create an industry-standard platform to train clinicians in ESA, thereby improving their skills in interacting with suicidal patients, and, ultimately, saving lives.

Study Type

Interventional

Enrollment (Actual)

213

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32611
        • University of Florida
      • Miami, Florida, United States, 33199
        • Florida International University
    • New York
      • New York, New York, United States, 10003
        • Icahn School of Medicine at Mount Sinai

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Clinician Participant

Inclusion Criteria:

  • a staff clinician or trainee in one of the Psychiatry outpatient clinics of the MSHS or Florida International University/Citrus Health Network outpatient clinics
  • have a caseload of 5 - 10 patients meeting PP inclusion and exclusion criteria.

Exclusion Criteria:

- non-approval for study participation by department chairman, training director or clinical supervisor.

Patient Participant

Inclusion Criteria:

  • currently in ongoing outpatient treatment at one of the recruitment clinics
  • have SI in the past month as defined by the CSSRS, have a lifetime history of actual SA as defined by the CSSRS or to have a confirmed psychiatric emergency room visit or hospitalization within the past two weeks.

Exclusion Criteria:

  • a need for hospitalization at the time of study enrollment
  • acute medical illness, cognitive impairment, linguistic limitation precluding understanding of the consent or research questions
  • and lack of contact information needed for follow up assessment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Emotional Self Awareness Group (Clinician participants)
Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
NO_INTERVENTION: Emotional Self Awareness Group (Patient participants)
Patients provided care by clinicians trained in ESA
SHAM_COMPARATOR: Control Group (Clinician participants)
The Control group CPs will engage in the same two VHI scenarios and will complete the TRQ-SF in response to each scenario without receiving the ESA feedback
Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
NO_INTERVENTION: Control Group (Patient participants)
Patients provided care by clinicians not receiving ESA feedback

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Suicide Crisis Inventory (SCI)
Time Frame: Baseline (T0)
A 49-item self-report instrument for the assessment of the severity of the Suicidal Crisis Syndrome (SCS), an acute state shown to correlate with a near-term suicide attempt. Items are rated by self-report on a five-point scale ranging from 0=not at all to 4=extremely. Full scale from 0-196, with higher score indicating increased suicide risk.
Baseline (T0)
Suicide Crisis Inventory (SCI)
Time Frame: 6 weeks (T3 = One month after T2)
A 49-item self-report instrument for the assessment of the severity of the Suicidal Crisis Syndrome (SCS), an acute state shown to correlate with a near-term suicide attempt. Items are rated by self-report on a five-point scale ranging from 0=not at all to 4=extremely. Full scale from 0-196, with higher score indicating increased suicide risk.
6 weeks (T3 = One month after T2)
Suicide Crisis Inventory (SCI)
Time Frame: 10 weeks (T4 = One month after T3)
A 49-item self-report instrument for the assessment of the severity of the Suicidal Crisis Syndrome (SCS), an acute state shown to correlate with a near-term suicide attempt. Items are rated by self-report on a five-point scale ranging from 0=not at all to 4=extremely. Full scale from 0-196, with higher score indicating increased suicide risk.
10 weeks (T4 = One month after T3)
Beck Scale for Suicide Ideation (BSS)
Time Frame: Baseline (T0)
A well validated 21-item self-report measure of active and passive suicidal desires will be used to assess severity of patient SI pre- and post-training. Scores on each item range from 0 to 2, full scale from 0-42, with higher scores indicating greater severity of SI.
Baseline (T0)
Beck Scale for Suicide Ideation (BSS)
Time Frame: 6 weeks (T3 = One month post T2)
A well validated 21-item self-report measure of active and passive suicidal desires will be used to assess severity of patient SI pre- and post-training. Scores on each item range from 0 to 2, full scale from 0-42, with higher scores indicating greater severity of SI.
6 weeks (T3 = One month post T2)
Beck Scale for Suicide Ideation (BSS)
Time Frame: 10 weeks (T4 = One month after T3)
A well validated 21-item self-report measure of active and passive suicidal desires will be used to assess severity of patient SI pre- and post-training. Scores on each item range from 0 to 2, full scale from 0-42, with higher scores indicating greater severity of SI.
10 weeks (T4 = One month after T3)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
TRQ-SF (Therapist Response Questionnaire Short Form)
Time Frame: Baseline (T0)
10-item, Likert-type scale designed to capture clinicians' emotional responses to acutely suicidal patients. TRQ-SF individual item scores range from 0 (Not at all) to 4 (Extremely). The scale probes suicide-related negative emotional response to patients with three sub-scales: Affiliation (5 items), Distress (3 items), and Hopefulness (2 items). The potential range for TRQ total scores is 0-40. Higher score indicate higher risk of suicide.
Baseline (T0)
TRQ-SF (Therapist Response Questionnaire Short Form)
Time Frame: 1 week (T1)
10-item, Likert-type scale designed to capture clinicians' emotional responses to acutely suicidal patients. TRQ-SF individual item scores range from 0 (Not at all) to 4 (Extremely). The scale probes suicide-related negative emotional response to patients with three sub-scales: Affiliation (5 items), Distress (3 items), and Hopefulness (2 items). The potential range for TRQ total scores is 0-40. Higher score indicate higher risk of suicide.
1 week (T1)
TRQ-SF (Therapist Response Questionnaire Short Form)
Time Frame: 2 weeks (T2)
10-item, Likert-type scale designed to capture clinicians' emotional responses to acutely suicidal patients. TRQ-SF individual item scores range from 0 (Not at all) to 4 (Extremely). The scale probes suicide-related negative emotional response to patients with three sub-scales: Affiliation (5 items), Distress (3 items), and Hopefulness (2 items). The potential range for TRQ total scores is 0-40. Higher score indicate higher risk of suicide.
2 weeks (T2)
TRQ-SF (Therapist Response Questionnaire Short Form)
Time Frame: 6 weeks (T3 = One month post T2)
10-item, Likert-type scale designed to capture clinicians' emotional responses to acutely suicidal patients. TRQ-SF individual item scores range from 0 (Not at all) to 4 (Extremely). The scale probes suicide-related negative emotional response to patients with three sub-scales: Affiliation (5 items), Distress (3 items), and Hopefulness (2 items). The potential range for TRQ total scores is 0-40. Higher score indicate higher risk of suicide.
6 weeks (T3 = One month post T2)
TRQ-SF (Therapist Response Questionnaire Short Form)
Time Frame: 10 weeks (T4 = One month after T3)
10-item, Likert-type scale designed to capture clinicians' emotional responses to acutely suicidal patients. TRQ-SF individual item scores range from 0 (Not at all) to 4 (Extremely). The scale probes suicide-related negative emotional response to patients with three sub-scales: Affiliation (5 items), Distress (3 items), and Hopefulness (2 items). The potential range for TRQ total scores is 0-40. Higher score indicate higher risk of suicide.
10 weeks (T4 = One month after T3)
Empathic Communication Coding System (ECCS)
Time Frame: 1 week (T1)
An expert-rated scale developed to code empathetic opportunities, defined as an explicit, clear, and direct statement of emotion, progress, or challenge by the patient. The ECCS also codes healthcare providers' verbal responses to these opportunities ranging from level 6 to level 0, denial of patient's perspective. The CPs' responses to the empathetic opportunities presented by the VHI will be coded with this scale. Full scale from 0-6, with higher score indicating more shared feeling or experience.
1 week (T1)
Empathic Communication Coding System (ECCS)
Time Frame: 2 weeks (T2)
An expert-rated scale developed to code empathetic opportunities, defined as an explicit, clear, and direct statement of emotion, progress, or challenge by the patient. The ECCS also codes healthcare providers' verbal responses to these opportunities ranging from level 6 to level 0, denial of patient's perspective. The CPs' responses to the empathetic opportunities presented by the VHI will be coded with this scale. Full scale from 0-6, with higher score indicating more shared feeling or experience.
2 weeks (T2)
Columbia Suicide-Severity Rating Scale (CSSRS)
Time Frame: Baseline (T0)
A semi-structured interview of current and past suicidal thoughts and behaviors. Full range from 0 to 9, with higher score indicating higher intensity suicidal ideation.
Baseline (T0)
Columbia Suicide-Severity Rating Scale (CSSRS)
Time Frame: 10 weeks (T4 = One month after T3)
A semi-structured interview of current and past suicidal thoughts and behaviors. Full range from 0 to 9, with higher score indicating higher intensity suicidal ideation.
10 weeks (T4 = One month after T3)
Working Alliance Inventory Short Form (WAI)
Time Frame: Baseline (T0)

Well-validated 12 item, 7-point Likert scale, self-report patient and clinician questionnaire with demonstrated predictive value for psychotherapeutic treatment adherence and outcomes. Full scale from 12-84, with higher scores indicating better alliance.

The WAI-SR is a patient-rated questionnaire. Patients rate items on a 5-point Likert scale anchored at each end with 'rarely or never' (1) and 'always' (5). The full score range from 5 to 20. Higher scores indicate a better therapeutic alliance.

Baseline (T0)
Working Alliance Inventory Short Form (WAI)
Time Frame: 6 weeks (T3 = One month post T2)

Well-validated 12 item, 7-point Likert scale, self-report patient and clinician questionnaire with demonstrated predictive value for psychotherapeutic treatment adherence and outcomes. Full scale from 12-84, with higher scores indicating better alliance.

The WAI-SR is a patient-rated questionnaire. Patients rate items on a 5-point Likert scale anchored at each end with 'rarely or never' (1) and 'always' (5). The full score range from 5 to 20. Higher scores indicate a better therapeutic alliance.

6 weeks (T3 = One month post T2)
Working Alliance Inventory Short Form (WAI)
Time Frame: 10 weeks (T4 = One month after T3)

Well-validated 12 item, 7-point Likert scale, self-report patient and clinician questionnaire with demonstrated predictive value for psychotherapeutic treatment adherence and outcomes. Full scale from 12-84, with higher scores indicating better alliance.

The WAI-SR is a patient-rated questionnaire. Patients rate items on a 5-point Likert scale anchored at each end with 'rarely or never' (1) and 'always' (5). The full score range from 5 to 20. Higher scores indicate a better therapeutic alliance.

10 weeks (T4 = One month after T3)
Clinician Prediction Scale (CPS)
Time Frame: 1 week (T1)
A one-item 10-point Likert Scale will be used to assess clinicians' judgement of patient suicide risk. Full score from 0-10, with higher score indicating higher risk of making a suicide attempt in the next 6 months if untreated.
1 week (T1)
Clinician Prediction Scale (CPS)
Time Frame: 2 weeks (T2)
A one-item 10-point Likert Scale will be used to assess clinicians' judgement of patient suicide risk. Full score from 0-10, with higher score indicating higher risk of making a suicide attempt in the next 6 months if untreated.
2 weeks (T2)
VHI training utility survey
Time Frame: 2 weeks (T2)
CPs ratings of satisfaction with the VHI through a satisfaction survey completed online at the 2nd VHI interaction. The survey has six items adapted from the Maastricht Assessment of Simulated Patients. Total score from 0-36 with higher score indicating higher satisfaction with virtual human interaction.
2 weeks (T2)
Consultation and Relational Empathy (CARE)
Time Frame: Baseline (T0)
A well-validated 10-item questionnaire that measures patient's perception of healthcare provider's empathy, with each item measured on a 5-point scale: Poor =1, Fair=2, Good=3, Very Good=4, Excellent=5. Full score from 10-50, with higher score indicating better healthcare provider's empathy perceived by the patient.
Baseline (T0)
Consultation and Relational Empathy (CARE)
Time Frame: 6 weeks (T3 = One month post T2)
A well-validated 10-item questionnaire that measures patient's perception of healthcare provider's empathy, with each item measured on a 5-point scale: Poor =1, Fair=2, Good=3, Very Good=4, Excellent=5. Full score from 10-50, with higher score indicating better healthcare provider's empathy perceived by the patient.
6 weeks (T3 = One month post T2)
Consultation and Relational Empathy (CARE)
Time Frame: 10 weeks (T4 = One month after T3)
A well-validated 10-item questionnaire that measures patient's perception of healthcare provider's empathy, with each item measured on a 5-point scale: Poor =1, Fair=2, Good=3, Very Good=4, Excellent=5. Full score from 10-50, with higher score indicating better healthcare provider's empathy perceived by the patient.
10 weeks (T4 = One month after T3)
Medication Adherence Rating Scale (MARS)
Time Frame: Baseline (T0)
Well-validated 8-item self-report instrument measuring patient's medication adherence and barriers to it. Full scale is from 0-10, with higher score indicating better adherence.
Baseline (T0)
Medication Adherence Rating Scale (MARS)
Time Frame: 6 weeks (T3 = One month post T2)
Well-validated 8-item self-report instrument measuring patient's medication adherence and barriers to it. Full scale is from 0-10, with higher score indicating better adherence.
6 weeks (T3 = One month post T2)
Medication Adherence Rating Scale (MARS)
Time Frame: 10 weeks (T4 = one month after T3)
Well-validated 8-item self-report instrument measuring patient's medication adherence and barriers to it. Full scale is from 0-10, with higher score indicating better adherence.
10 weeks (T4 = one month after T3)
Facial Affective Coding System (FACS)
Time Frame: 1 week (T1)
The Facial Action Coding System (FACS) is a comprehensive, anatomically based system for describing all visually discernible facial movement, breaking down facial expressions into individual components of muscle movement. FACS, using Noldus FaceReader Software, will be applied to video recordings of clinicians interacting with the VHs. The system will evaluate clinicians' facial affective behavior to detect the presence of basic emotions, including sadness, happiness, anger, disgust, surprise, and fear. Duration of analyzed video segments in minutes and seconds, as well as computerized character values of emotions detected by the software, will be provided for analysis.
1 week (T1)
Facial Affective Coding System (FACS)
Time Frame: 2 weeks (T2)
The Facial Action Coding System (FACS) is a comprehensive, anatomically based system for describing all visually discernible facial movement, breaking down facial expressions into individual components of muscle movement. FACS, using Noldus FaceReader Software, will be applied to video recordings of clinicians interacting with the VHs. The system will evaluate clinicians' facial affective behavior to detect the presence of basic emotions, including sadness, happiness, anger, disgust, surprise, and fear. Duration of analyzed video segments in minutes and seconds, as well as computerized character values of emotions detected by the software, will be provided for analysis.
2 weeks (T2)
Proportion of Nonsensical VH Responses
Time Frame: 1 week (T1)
The number of nonsensical and sensical VH responses will be manually coded. Members of the research team will code nonsensical and sensical VH responses through assessment clinician transcripts with the VH, which are generated automatically after each VH interaction. The proportion of nonsensical to sensical counts per transcript will be calculated, and items are rated nominally as 0 = nonsensical and 1 = sensical.
1 week (T1)
Proportion of Nonsensical VH Responses
Time Frame: 2 weeks (T2)
The number of nonsensical and sensical VH responses will be manually coded. Members of the research team will code nonsensical and sensical VH responses through assessment clinician transcripts with the VH, which are generated automatically after each VH interaction. The proportion of nonsensical to sensical counts per transcript will be calculated, and items are rated nominally as 0 = nonsensical and 1 = sensical.
2 weeks (T2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Igor Galynker, MD, PhD, Icahn School of Medicine at Mount Sinai
  • Principal Investigator: Adriana Foster, MD, Florida International Univerisity
  • Principal Investigator: Benjamin Lok, PhD, University of Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 9, 2019

Primary Completion (ACTUAL)

May 31, 2022

Study Completion (ACTUAL)

June 5, 2022

Study Registration Dates

First Submitted

September 30, 2019

First Submitted That Met QC Criteria

October 11, 2019

First Posted (ACTUAL)

October 15, 2019

Study Record Updates

Last Update Posted (ACTUAL)

November 23, 2022

Last Update Submitted That Met QC Criteria

November 20, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • GCO 18-1346

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicide

Clinical Trials on Emotional Self Awareness (ESA) Individual Feedback

3
Subscribe